Slow Parkinson progression with telmisartan
- Trial ID
- NCT07207057
- Official Title
- Edmond J Safra, Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) - a Multi-arm Multi-stage Platform Trial for Potential Disease Modifying Approaches.
- Goal
- Slow Parkinson progression with telmisartan
- Phase
- PHASE3
- Status
- RECRUITING
- Sponsor
- University College, London
- Study Type
- INTERVENTIONAL
- Enrollment
- 1200 participants
- Conditions
- Parkinsons Disease (PD)
- Interventions
- Placebo, Telmisartan, Terazosin (Hytrin)
Summary For Families
The goal is to see if two repurposed drugs can slow Parkinson's progression and protect neurons, offering possible disease modification rather than only treating symptoms. Telmisartan blocks angiotensin II type 1 receptors to lower blood pressure and may reduce brain inflammation and oxidative stress, so it would be taken alongside usual Parkinson's medicines like levodopa with monitoring of blood pressure, potassium and kidney function. Terazosin is an alpha-1 blocker that also activates the enzyme PGK1 to boost cellular energy and ATP in neurons, which could make cells more resilient; it can cause dizziness or low blood pressure so people on other alpha blockers or with symptomatic hypotension are excluded. The trial is enrolling about 1,200 adults aged 30 and up with neurologist-diagnosed Parkinson's who have been on levodopa or a dopamine agonist for at least two months, excluding those with dementia, certain genetic forms, recent experimental drug exposure, serious heart or kidney disease, problematic low blood pressure, or pregnancy.
Locations
- UCLH, London, United Kingdom
- Clinical Ageing Research Unit, Newcastle, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Placebo. The goal is to see if two repurposed drugs can slow Parkinson's progression and protect neurons, offering possible disease modification rather than only treating symptoms. Telmisartan blocks angiotensin II type 1 receptors to lower blood pressure and may reduce brain inflammation and oxidative stress, so it would be taken alongside usual Parkinson's medicines like levodopa with monitoring of blood pressure, potassium and kidney function. Terazosin is an alpha-1 blocker that also activates the enzyme PGK1 to boost cellular energy and ATP in neurons, which could make cells more resilient; it can cause dizziness or low blood pressure so people on other alpha blockers or with symptomatic hypotension are excluded. The trial is enrolling about 1,200 adults aged 30 and up with neurologist-diagnosed Parkinson's who have been on levodopa or a dopamine agonist for at least two months, excluding those with dementia, certain genetic forms, recent experimental drug exposure, serious heart or kidney disease, problematic low blood pressure, or pregnancy.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 3 trial is estimated to last approximately 5 years and 8 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.